Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) - USD ($)							1 Months Ended	3 Months Ended		6 Months Ended
	May 20, 2024	May 13, 2024	May 13, 2022	Jun. 16, 2021	Mar. 26, 2021	Jul. 18, 2016	May 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Apr. 25, 2024	Dec. 31, 2023	Aug. 24, 2022
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value			$ 470,000
Treasury Stock, Common, Shares			13,902
Legal fee							$ 473,000
Shares return, value							$ 19,000
Shares return							13,902
Common stock, shares issued								2,234,328		2,234,328			1,380,633
Accounts payable, current								$ 1,717,000		$ 1,717,000			$ 4,328,000
Beneficial ownership percentage								5.00%		5.00%
Stock issued during period, value, issued for services										$ 1,500,000	$ 315,000
Research and development expense								$ 1,784,000	$ 2,095,000	2,561,000	3,745,000
Scientific Research Agreement [Member]
Loss Contingencies [Line Items]
Aggregate research and development expense				$ 2,100,000
Research and development expense										0	192,000
Unbilled and unaccrued amounts								0		0
Sponsored Research Agreement [Member]
Loss Contingencies [Line Items]
Aggregate research and development expense	$ 1,700,000
Research and development expense										863,000	0
Unbilled and unaccrued amounts								$ 862,000		862,000
2016 Patent Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense										0	0
Proceeds from upfront amount		$ 145,000				$ 200,000
Maintenance fee		100,000				100,000
Performance milestone payments		3,100,000				3,100,000
Sales milestone payments		1,000,000				1,000,000
Gross sales		250,000,000				250,000,000
Sales revenue		5,000,000				5,000,000
Cumulative gross sales		500,000,000				$ 500,000,000
[custom:RoyaltyExpenseYearOne]		250,000
[custom:RoyaltyExpenseYearTwoThroughFive]		2,000,000
[custom:RoyaltyExpenseYearAfterSix]		$ 5,000,000
2016 Patent Exclusive License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Net sales percentage		1.00%				4.00%
2016 Patent Exclusive License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Net sales percentage		5.00%				6.00%
2016 Patent Exclusive License Agreement [Member] \| 2017 through 2012 [Member]
Loss Contingencies [Line Items]
Maintenance fee						$ 200,000
2016 Patent Exclusive License Agreement [Member] \| 2022 [Member]
Loss Contingencies [Line Items]
Annual royalty payments						250,000
2016 Patent Exclusive License Agreement [Member] \| 2025 [Member]
Loss Contingencies [Line Items]
Maintenance fee		$ 50,000
Annual royalty payments						2,000,000
2016 Patent Exclusive License Agreement [Member] \| 2027 [Member]
Loss Contingencies [Line Items]
Annual royalty payments						$ 5,000,000
2021 Patent License Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense										$ 145,000	$ 0
Maintenance fee					$ 2,000,000
Annual royalty payments					250,000
Performance milestone payments					3,100,000
Sales milestone payments					1,000,000
Gross sales					250,000,000
Sales revenue					5,000,000
Cumulative gross sales					500,000,000
Upfront license fee					20,000
License maintenance fee, receivable					$ 5,000
2021 Patent License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Net sales percentage					2.50%
2021 Patent License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Net sales percentage					5.00%
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Common stock, shares issued								127,597	44,793	127,597	44,793
Accounts payable, current								$ 810,000	$ 1,120,000	$ 810,000	$ 1,120,000
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Equity method investment, ownership percentage												9.90%		4.90%